nach oben

Clinical & Experimental Metastasis

Erschienen in:

06.07.2018 | Meeting report

11th International Symposium on Minimal Residual Cancer (ISMRC): 3–5 May 2018, Montpellier, France

verfasst von: Catherine Alix-Panabières, Klaus Pantel

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Excerpt

International ISMRC meetings started in 1996 and have established themselves, every other year, as a premier event focusing on minimal residual cancer in patients with solid tumors. After great cities like Munich, Berlin, Oslo, San Francisco, Hamburg, Athens, Osaka and Paris, the 11th International Symposium of Minimal Residual Cancer (ISMRC) took place May 3–5 2018 at the convention center ‘Corum’ in Montpellier, France (http://www.ismrc2018.com). Forty-two international key opinion leaders and experts in the field of cancer have been invited; thirty different sponsors accepted to support this important congress and 400 participants from 31 different countries registered proposing 119 abstracts. …

Massague J, Obenauf AC (2016) Metastatic colonization by circulating tumour cells. Nature 529(7586):298–306CrossRefPubMedPubMedCentral

Sleeman JP (2015) Pre-metastatic conditioning of organ microenvironments by tumors: beyond preparing the soil. J Mol Med 93(11):1171–1172CrossRefPubMed

Zheng H et al (2017) Therapeutic antibody targeting tumor- and osteoblastic niche-derived jagged sensitizes bone metastasis to chemotherapy. Cancer Cell 32(6):731–747CrossRefPubMed

Puisieux A et al (2018) Cellular pliancy and the multistep process of tumorigenesis. Cancer Cell 33(2):164–172CrossRefPubMed

Banyard J et al (2014) Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer 14:387CrossRefPubMedPubMedCentral

Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168(4):670–691CrossRefPubMedPubMedCentral

Voon DC et al (2017) The EMT spectrum and therapeutic opportunities. Mol Oncol 11(7):878–891CrossRefPubMedPubMedCentral

Francart ME et al (2018) Epithelial-mesenchymal plasticity and circulating tumor cells: travel companions to metastases. Dev Dyn 247(3):432–450CrossRefPubMed

Nieto MA et al (2016) Emt: 2016. Cell 166(1):21–45CrossRefPubMed

10.

Brabletz T et al (2018) EMT in cancer. Nat Rev Cancer 18(2):128–134CrossRefPubMed

11.

Dalerba P et al (2016) CDX2 as a prognostic Biomarker in stage II and stage III colon cancer. N Engl J Med 374(3):211–222CrossRefPubMedPubMedCentral

12.

Sikandar SS et al (2017) Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. Nat Commun 8(1):1669CrossRefPubMedPubMedCentral

13.

Mlecnik B et al (2016) Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44(3):698–711CrossRefPubMed

14.

McGranahan N et al (2017) Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171(6):1259–1271CrossRefPubMedPubMedCentral

15.

Thomas F et al (2017) The importance of cancer cells for animal evolutionary ecology. Nat Ecol Evol 1(11):1592–1595CrossRefPubMed

16.

Pantel K, Alix-Panabieres C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16(9):398–406CrossRefPubMed

17.

Bardelli A, Pantel K (2017) Liquid biopsies, what we do not know (Yet). Cancer Cell 31(2):172–179CrossRefPubMed

18.

Alix-Panabieres C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6(5):479–491CrossRefPubMed

19.

Alix-Panabieres C, Pantel K (2014) Challenges in circulating tumour cell research. Nat Rev Cancer 14(9):623–631CrossRefPubMed

20.

Chan KCA et al (2017) Analysis of plasma epstein-barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 377(6):513–522CrossRefPubMed

21.

Zhang J, Chen K, Fan ZH (2016) Circulating tumor cell isolation and analysis. Adv Clin Chem 75:1–31CrossRefPubMedPubMedCentral

22.

Muller C et al (2014) Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 6(247):247ra101CrossRefPubMed

23.

Boral D et al (2017) Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun 8(1):196CrossRefPubMedPubMedCentral

24.

Ulz P et al (2016) Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet 48(10):1273–1278CrossRefPubMed

25.

Pantel K, Hayes DF (2018) Disseminated breast tumour cells: biological and clinical meaning. Nat Rev Clin Oncol 15(3):129–131CrossRefPubMed

26.

Paoletti C et al (2018) Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Res 78(4):1110–1122CrossRefPubMed

27.

Ferrarini A et al (2018) A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. PLoS ONE 13(3):e0193689CrossRefPubMedPubMedCentral

28.

Bidard FC et al (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15(4):406–414CrossRefPubMed

29.

Pailler E et al (2017) Circulating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK-rearranged non-small cell lung cancer patients. Cancer Res 77(9):2222–2230CrossRefPubMed

30.

Tie J et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8(346):346ra92CrossRefPubMedPubMedCentral

31.

Schochter F et al (2018) Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells—first results of the SUCCESS C endocrine treatment sub-study. Oncol Res Treat 41(3):93–98CrossRefPubMed

32.

Lorente D et al. (2018) Circulating tumor cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann Oncol

33.

Murtaza M et al (2015) Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 6:8760CrossRefPubMedPubMedCentral

34.

Huang SK, Hoon DS (2016) Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol 10(3):450–463CrossRefPubMed

35.

Mazel M et al (2015) Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 9(9):1773–1782CrossRefPubMedPubMedCentral

36.

Strati A et al (2017) Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann Oncol 28(8):1923–1933CrossRefPubMed

37.

Ilie M et al (2018) Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol 29(1):193–199CrossRefPubMed

38.

Nicolazzo C et al (2016) Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep 6:31726CrossRefPubMedPubMedCentral

39.

Antonarakis ES et al (2017) Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol 35(19):2149–2156CrossRefPubMedPubMedCentral

40.

Scher HI et al (2016) Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2(11):1441–1449CrossRefPubMedPubMedCentral

41.

Cayrefourcq L et al (2015) Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 75(5):892–901CrossRefPubMed

42.

Baccelli I et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544CrossRefPubMed

43.

Hodgkinson CL et al (2014) Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 20(8):897–903CrossRefPubMed

44.

Amorim MG et al (2017) A total transcriptome profiling method for plasma-derived extracellular vesicles: applications for liquid biopsies. Sci Rep 7(1):14395CrossRefPubMedPubMedCentral

45.

Hoshino A et al (2015) Tumour exosome integrins determine organotropic metastasis. Nature 527(7578):329–335CrossRefPubMedPubMedCentral

46.

Best MG et al (2015) RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28(5):666–676CrossRefPubMedPubMedCentral

47.

Ramalingam N, Jeffrey SS (2018) Future of liquid biopsies with growing technological and bioinformatics studies: opportunities and challenges in discovering tumor heterogeneity with single-cell level analysis. Cancer J 24(2):104–108CrossRefPubMed

Titel: 11th International Symposium on Minimal Residual Cancer (ISMRC): 3–5 May 2018, Montpellier, France
verfasst von: Catherine Alix-Panabières
Klaus Pantel
Publikationsdatum: 06.07.2018
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 3/2018
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-018-9909-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

11th International Symposium on Minimal Residual Cancer (ISMRC): 3–5 May 2018, Montpellier, France

Excerpt

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Abstracts from the 11th International Symposium on Minimal Residual Disease, 3–5 May 2018, Montpellier, France

Hemodynamic shear stress induces protective autophagy in HeLa cells through lipid raft-mediated mechanotransduction

Isolated pancreatic metastases from renal cell carcinoma: an outcome of a special metastatic pathway or of specific tumor cell selection?

Long non-coding RNA p10247, high expressed in breast cancer (lncRNA-BCHE), is correlated with metastasis

Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines

ETS1 regulates Twist1 transcription in a Kras G12D /Lkb1−/− metastatic lung tumor model of non-small cell lung cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie